Latest News and Press Releases

SLOUGH, U.K., Jan. 5, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces that it commenced dosing of patients in the first of two pivotal Phase III studies ("PRECISE-1") for...

Slough, U.K., Dec. 10, 2003 (PRIMEZONE) -- Celltech Group Plc: SCHEDULE 10 NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Name of company Celltech Group plc 2. Name of shareholder having a...

LONDON, Dec. 01, 2003 (PRIMEZONE) -- lltech Group plc (LSE:CCH)(NYSE:CLL) today announces that it will regain full rights to CDP 870, its PEGylated anti-TNF-alpha antibody fragment, from Pfizer...

LONDON, Dec. 1, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces the appointment of Dr. Grahaem Brown as Director of Development. Grahaem has over 20 years of drug...

SLOUGH, UK, Nov. 19, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) announced today that it has completed its integration of Oxford GlycoSciences (OGS), which was acquired in May 2003....

SLOUGH, U.K., Nov. 19, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) announced today a reorganisation of its R&D operations designed to rebalance resources between its research and...

SLOUGH, U.K., Nov. 13, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announced an update on the clinical development programme for CDP 870, its PEGylated anti-TNF-alpha antibody...

SLOUGH, U.K., Oct. 30, 2003 (PRIMEZONE) -- Celltech Pharmaceuticals, a division of Celltech Group plc (LSE:CCH) (NYSE:CLL), announces that it has licensed European sales and marketing rights to Xyrem...

SLOUGH, U.K., Oct. 28, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announced the achievement of a milestone in its agreement with Amgen Inc. for the research, development and...

SLOUGH, UK, Sept. 24, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) announces that Merck & Co., Inc. (NYSE:MRK) (Pink Sheets:MCKIF) has exercised its option to extend the...